Navigation Links
First genome sequencing clinical trial for triple negative cancer points to new treatments
Date:12/8/2011

PHOENIX, Ariz. -- Initial results from an ongoing clinical trial, the first designed to examine the utility of whole-genome sequencing for triple negative breast cancer, were reported today during the CRTC-AACR San Antonio Breast Cancer Symposium.

The results indicate activation of targets not previously associated with triple negative disease and could point toward new treatment strategies. Based on mutations uncovered by sequencing, physicians recommended the women enter treatment protocols for either existing drugs or new agents being evaluated in pharma-sponsored clinical trials.

Triple negative breast tumors, which make up nearly 20 percent of breast cancers, do not respond to treatment with targeted therapies such as Herceptin (trastuzumab).

Of eleven tumors sequenced to date, each was genomically unique, but commonalities were observed. Some patients displayed amplified genes in the RAS pathway; one patient had amplification of the BRAF oncogene, as well as activation of a growth pathway known as the MEK/AKT pathway. This patient displayed an impressive response to a MEK/AKT inhibitor currently in a phase I clinical study.

"Those results are quite striking considering that these are women with advanced disease," said Joyce O'Shaughnessy, M.D., who presented the data. "If MEK/AKT activation is found to be present in a substantial fraction of triple negative patients, inhibitors of this pathway could prove a significant tool in fighting this disease."

Dr. O'Shaughnessy is medical director and co-chair of the Breast Cancer Research Committee, US Oncology Research; a practicing oncologist with Texas Oncology; and the Celebrating Women Chair of Breast Cancer Research at Baylor Charles A. Sammons Cancer Center.

"This is among the largest studies of a single tumor type in which whole genome sequencing is being used to identify potential options for targeted treatment," said John Carpten, Ph.D., director of the Integrated Cancer Genomics Division at the Translational Genomics Research Institute (TGen). "As the field of genomic medicine matures, this study is sure to provide key early insights into how sequencing can best be utilized in the clinic."


'/>"/>
Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Medical Training School, Pima Medical Institute Offering First Bachelor's Degree Program
2. Retired Military Brass Support First Ladys Call to Reduce Child Obesity, Improve Nutrition
3. NASBE Supports First Lady Michelle Obama in Fight Against Childhood Obesity
4. PolicyLink CEO Angela Glover Blackwell Released the Following Statement on First Lady Michelle Obamas Childhood Obesity Initiative
5. MSU launches first anti-counterfeiting research program
6. AMA Joins First Lady in Fight Against Childhood Obesity
7. National Wildlife Federation Says Outdoor Time for Kids Can Help First Lady Achieve Her “Let's Move” Goal
8. First blinded study of venous insufficiency prevalence in MS shows promising results
9. Akron Institute of Herzing University Launches Its First Bachelors Degree Programs to Prepare Students for Even Greater Success in Business, Health Care and IT
10. First Gene Variants Linked to Stuttering Discovered
11. FAB-HOMES™ Presents First Passive House Collection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... i2i Population Health, a national leader ... , “Cary’s broad financial background is an excellent fit for i2i,” ... and day-to-day financial operations skills we need to take the company to the next ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... detect, and eliminate cyber threats in real-time, today announced a strategic partnership with ... enable customers to monitor, respond and protect their critical information assets and infrastructure, ...
(Date:1/24/2017)... , ... January 24, 2017 , ... Center for ... century leadership, has named Hector M. Chavez, Manager, Employee & Labor Relations at ... - as its Hispanic Leader of the Month. City of Hope is committed to ...
(Date:1/24/2017)... ... January 24, 2017 , ... The results from the American Cancer ... good news for prostate cancer patients: incidents of cancer is down as is the ... the cancer death rate has dropped from its peak of 215.1 in 1991 to ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... A yellow ... lives in the last month. Yellow fever is primarily spread through contact with infected ... community’s focus on how to prevent its spread. , According to multiple health organizations, ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Research Future has a half cooked research report on global Plastic ... & Integumentary System is growing rapidly and expected to reach USD ... Market Highlights ... Plastic Surgery & Integumentary System Market has been evaluated as a ... growth figures and thriving in the coming future. There has been ...
(Date:1/24/2017)... Analysis of the Liquid Biopsy Market by ... - our new study reveals trends, R&D progress, and predicted revenues ... involved in this sector you must read this brand new report. ... 2027, assessing data, trends, opportunities and business prospects there. ... Discover How to Stay Ahead ...
(Date:1/24/2017)... DIEGO , Jan. 24, 2017 ... in clinical materials management services, is pleased to ... of Operations. Kevin joins the Sherpa team to ... the highest level of service excellence. ... chain and pharmaceutical manufacturing industries. He has extensive ...
Breaking Medicine Technology: